CANbridge Pharmaceuticals 2025 Annual Report: Key Highlights and Investor Analysis

CANbridge Pharmaceuticals Inc. has released its annual report for the year ended December 31, 2025, providing comprehensive insights into its financial performance, business strategy, and operational milestones. Below, we detail the most critical points from the report, focusing on matters that are essential for shareholders and could significantly impact share value.

1. Financial Performance and Profitability

• Profitability Achieved: For the first time, CANbridge Pharmaceuticals reported IFRS profitability for the year, with a net profit of RMB 14.8 million, compared to a loss of RMB 442.6 million in 2024. This turnaround was driven by strict cost controls, a one-off gain from US lease termination, and operational efficiency initiatives.
• Revenue Growth: The company’s commercial products, including Hunterase^® and Livmarli^®, continued to see steady patient identification growth, supported by expanded commercial insurance coverage in dozens of cities.
• Cost Management: Research and development, selling and distribution, and administrative expenses all decreased substantially. The company adopted a prudent funding and treasury policy, with a focus on maintaining optimal financial position and minimal financial risks.
• Liquidity: As of December 31, 2025, the company had cash and bank balances of RMB 66.6 million, up significantly from RMB 10.5 million the previous year, mainly due to new financing from share subscriptions.

2. Strategic Partnerships and Commercial Milestones

• Strategic Partnership: In August 2025, CANbridge entered into a strategic partnership with Baheal Medical, significantly enhancing its commercial capabilities and market penetration for key products across Greater China.
• Product Approvals: The company’s class 1 innovative drug, Gaurunning^®, received NMPA (National Medical Products Administration of China) marketing approval and was included in China’s first commercial health insurance innovative drug list.
• Commercialization Teams: CANbridge established dedicated commercialization teams for approved and late-stage pipeline products, focusing on marketing, sales, medical affairs, and patient advocacy.

3. Capital Raising and Use of Proceeds

• Significant Share Subscriptions: On March 10, 2026, CANbridge allotted and issued 84,033,613 new shares to WuXi Biologics HealthCare Venture at HK\$2.38 per share, raising gross proceeds of approximately HK\$200 million. This capital injection is earmarked for research and development, marketing, loan repayment, and daily operations.
• Use of Proceeds: As of December 31, 2025, a substantial portion of the proceeds from earlier subscriptions remains unutilized, including HK\$21.7 million for marketing and promotion and HK\$8.3 million for R&D, with targeted deployment by the end of 2027.
• Gearing and Capital Ratios: The company reduced its bank loans from RMB 30.4 million to RMB 15.0 million and improved its current ratio from 9.4% to 24.2%, indicating a stronger liquidity position.

4. Shareholder and Corporate Governance Matters

• No Dividend: The board does not recommend the payment of a final dividend for 2025, prioritizing reinvestment in growth and R&D.
• Share Schemes: Share options and incentive plans remain a key component of employee and management compensation, with extensive details provided on outstanding options and RSUs under various schemes. As of December 31, 2025, 20,767,760 shares under the Pre-IPO Equity Incentive Plan remained available for issue.
• Board and Management: The roles of Chairman and CEO are still combined under Dr. Xue, deviating from the CG Code’s preferred separation but justified by the board due to Dr. Xue’s extensive experience and leadership.
• Corporate Governance: The company maintains rigorous internal controls, anti-corruption policies, and risk management frameworks, with compliance confirmed by independent auditors.

5. Key Risks and Uncertainties

• Going Concern Warning: Despite the return to profitability, the auditors have included a “Material Uncertainty related to Going Concern” in their report. The company’s ability to continue as a going concern depends on successful cost control, renewed banking facilities, supplier negotiations, licensing agreements, and product profitability. Failure in these areas could require asset write-downs and reclassification of liabilities.
• Customer Concentration: The largest customer accounted for 57.8% of total revenue, with the top five customers representing 100% of revenue, indicating significant customer concentration risk.
• Regulatory Risks: The company’s operations, especially in gene therapy, are subject to stringent PRC regulations, requiring complex contractual arrangements (VIE structure) to comply with foreign investment restrictions.
• No Outstanding Legal Proceedings: There were no material legal disputes or claims pending as of year-end.

6. Post-Reporting Period Events

• Share Subscription with WuXi Biologics: The share placement to WuXi Biologics HealthCare Venture, completed on March 10, 2026, is a major post-period event. This strengthens CANbridge’s capital base and signals strategic alignment with a major industry player.
• No Other Material Events: The company confirms no further significant events post year-end that would affect shareholder interests or require disclosure.

7. Additional Noteworthy Disclosures

• Zero Tolerance Policies: CANbridge upholds strict anti-corruption, anti-money laundering, and fair competition compliance, with whistleblower provisions and staff training to reinforce ethical standards.
• Employee Optimization: Workforce was reduced to 41 employees by year-end, with gender balance almost equal, as part of cost management amid a challenging macro environment.
• Major Supplier Risk: The largest supplier accounted for 25.2% of purchases, with the top five at 72.1%.

Conclusion: Shareholder Impact and Outlook

The 2025 annual report marks a pivotal year for CANbridge Pharmaceuticals, highlighted by its return to profitability, major capital injection, and successful product launches. However, the company’s future performance hinges on continued execution of its strategic initiatives, mitigation of concentration and regulatory risks, and prudent capital management. The going concern qualifier remains a key watchpoint for investors, as does the company’s reliance on a small number of customers and suppliers. The recent share placement with WuXi Biologics is a potentially positive catalyst, strengthening both the balance sheet and strategic capabilities.

Disclaimer: This article is for informational purposes only and should not be construed as investment advice. While efforts have been made to ensure accuracy, investors are advised to review the full CANbridge Pharmaceuticals 2025 Annual Report and consult their financial advisors before making investment decisions. The article may contain forward-looking statements subject to risks and uncertainties.

View CANBRIDGE-B Historical chart here